Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Gastrointestinal Stromal Tumors 6Leukemia, Myeloid, Chronic-Phase 4Leukemia 4Neoplasms 2Neoplasm Metastasis 2Melanoma 2Sarcoma 1Relapsed Pediatric Solid Tumor 1Mesothelioma 1Meningioma 1Leukemia, Myeloid 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1GIST 1Drug-Related Side Effects and Adverse Reactions 1Chordoma 1Central Nervous System Neoplasms 1Carcinoma, Adenoid Cystic 1Brain Neoplasms 1

Interventions

pembrolizumab 2Hyperthermic Intraperitoneal Chemotherapy 2Gemcitabine 2Cisplatin 2niraparib 1dostarlimab 1defactinib 1Vitamin B 12 1TroVax 1Thiostrepton 1Sorafenib 1Pemetrexed 1Oxaliplatin 1Nivolumab 1Mitomycin 1MAC321 1Leucovorin 1Immunotherapy, Adoptive 1Imatinib Mesylate 1IPI-549 1Folic Acid 1Dexamethasone 1Cytoreduction Surgical Procedures 1Bortezomib 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Mesothelioma × Imatinib Mesylate × Clear all
NCT00551252 2007-10-30

A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma

Gruppo Italiano MEsotelioma

Phase 2 Unknown
56 enrolled
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡